What Is an sBLA/sNDA? Label Expansion Filings Explained

You saw “sBLA” in a headline about Merck and Enhertu and didn’t know whether to care. You know what a BLA is, but the “s” changes everything. The drug is already approved. The company is asking the FDA to let them sell it to more patients. Sometimes that moves the stock 20%. Sometimes it moves it 2%. Here is how to tell the difference before you trade.

The solution: a sBLA (supplemental Biologics License Application) or sNDA (supplemental New Drug Application) is a filing to expand an already-approved drug’s label to a new indication, new patient population, new formulation, or new dosing regimen. The safety database already exists. The review focuses on whether the new data supports the new use. Supplemental applications get approved more often than initial ones, but they move mega-cap stocks less. Understanding both halves of that trade-off is the edge.

Step 1: Understand what “supplemental” means

When a drug gets its first FDA approval, the company files an initial NDA (small molecule) or BLA (biologic). That is the filing that makes or breaks small-cap biotech stocks. See our BLA vs NDA guide for how those work.

Once the drug is approved and on the market, the company can file supplemental applications to expand the label. The “s” in sBLA or sNDA means supplemental. The drug is already approved for something. The company wants it approved for something else.

A label expansion can take several forms:

• New indication. The drug works for a different disease. Example: Merck’s Keytruda started in melanoma in 2014 and has since added dozens of indications across lung cancer, head and neck, gastric, cervical, and more.
• New patient population. The drug works in a subset of patients it was not initially approved for. Example: Vertex’s Casgevy gene therapy was approved for sickle cell disease in adults, then expanded to children ages 2-11 in 2024. See our Casgevy children approval writeup.
• New formulation. The drug is reformulated for easier delivery. Example: Keytruda’s subcutaneous injection formulation (Keytruda QLEX), which lets patients avoid IV infusion.
• New dosing regimen. A different dose, schedule, or duration that works better or is more convenient.

Step 2: Learn why sBLAs get approved more often

The safety profile is already established. The FDA has already reviewed the drug’s safety database when it approved the initial application. For a supplemental filing, the agency focuses on whether the new efficacy data supports the new indication. The safety question is narrower: are there any new safety signals in the new patient population?

This means supplemental applications have higher approval rates than initial filings. The overall CRL base rate for initial NDAs and BLAs is roughly 37% between 2018 and 2022, per Avalere and FDA user-fee data. Supplemental applications clear that bar more easily because the drug is already on the market and the safety profile is known.

The review timeline can also be shorter. Under the PDUFA performance goals, the standard review target is 10 months for a supplemental application versus 12 months for an initial application. Priority review still applies at 6 months if the new indication addresses an unmet need. The full PDUFA framework is in our PDUFA date guide.

Step 3: Understand why sBLAs move mega-cap stocks less

Here is what most investors miss. A supplemental approval is higher-probability but lower-impact for the stock price. The approved drug’s revenue is already in the stock price.

When a $2 billion market cap biotech gets its first drug approved, the stock can double because the company goes from zero revenue to a real product. When a $500 billion pharma gets a label expansion on a drug that is already generating $10 billion a year, the stock barely moves. The incremental indication adds revenue, but it is marginal against the existing base.

Real example: Merck and Daiichi-Sankyo filed an sBLA for Enhertu (trastuzumab deruxtecan) in HER2-positive early breast cancer based on the DESTINY-Breast05 trial. The trial showed a 53% reduction in the risk of invasive disease recurrence or death versus trastuzumab plus pertuzumab. The FDA granted Priority Review and Breakthrough Therapy designation in December 2025. The sBLA was approved on July 7, 2026. This was a major clinical result that expands Enhertu from metastatic to early-stage breast cancer, adding 16,000 eligible US patients per year. But Merck is a $500 billion company. A label expansion, even a meaningful one, moves the needle a fraction of a percent. See our Enhertu DESTINY-Breast09 coverage for the competitive context.

Step 4: Spot the exception: when an sBLA opens a fundamentally new market

Not all sBLAs are marginal. When a supplemental approval opens a patient population that is materially larger than the approved indication, the stock can still move. The Enhertu sBLA is a good example: moving from metastatic breast cancer (a smaller, sicker population) to early-stage adjuvant treatment (a much larger population treated with curative intent) is a step-change in addressable market, not an incremental tweak.

Another example: Vertex’s Casgevy sBLA expanding to children ages 2-6. The initial approval was for patients 12 and older. Expanding to younger children does not just add patients, it makes Casgevy the standard of care earlier in the disease course, which shifts the treatment standard. For a diversified company like Vertex, the stock move is modest. But the revenue trajectory shifts.

The rule of thumb: if the sBLA doubles or triples the addressable patient population, it can move even a mega-cap. If it adds a similar indication to an already-broad label, it will not.

Step 5: Find sBLAs on the FDA calendar

Supplemental applications show up on the same FDA calendars as initial filings. BioPharmCatalyst lists sBLA and sNDA PDUFA dates alongside initial BLAs and NDAs. The difference is in the context, not the calendar entry.

When you see a PDUFA date on the calendar, check whether it is an initial filing or a supplemental one. The calendar usually notes this. If it says “sBLA” or “supplemental,” the drug is already approved and you are trading a label expansion. If it says “BLA” or “NDA” without the “s,” it is an initial filing and the binary risk is higher.

Our Q3 2026 FDA calendar tracks confirmed PDUFA dates across both initial and supplemental filings. Cross-reference any sBLA you find there against the drug’s current approved label on the FDA’s website to understand how big the expansion is.

Step 6: Read the new indication data, not the old approval

The data that matters for an sBLA is the trial data supporting the new indication, not the trial that got the drug approved originally. For Enhertu’s sBLA, the relevant trial is DESTINY-Breast05, a Phase 3 trial in HER2+ early breast cancer after neoadjuvant therapy. The 53% risk reduction in invasive disease recurrence or death is the number that drove the approval.

Read the primary endpoint and the effect size the same way you would for an initial filing. Our guide to reading clinical trial press releases walks through how to find the numbers that actually predict an approval. The same rules apply: check the primary endpoint, the p-value, the confidence interval, and the safety data in the new population.

Common mistakes

• Trading an sBLA like an initial BLA. Supplemental applications have higher approval rates and lower stock-moving potential.
• Assuming the safety profile carries over completely. The safety database exists, but a new patient population can surface new adverse events.
• Ignoring the addressable market question. An sBLA that adds a similar indication to a broad label is a nonevent for the stock. An sBLA that doubles the patient population can move even a mega-cap.
• Forgetting that the FDA calendar does not distinguish initial from supplemental. A PDUFA date on the calendar looks the same whether it is an initial BLA or an sBLA.
• Not reading the confirmatory data. The PDUFA date is the deadline; the trial data is the reason. An sBLA on weak Phase 2 data can still get a CRL.

Final checklist

• Filing type identified: sBLA (biologic) or sNDA (small molecule), not initial BLA/NDA
• New indication, population, formulation, or dosing regimen confirmed
• Addressable market impact assessed: marginal vs step-change
• Trial data for the new indication reviewed (primary endpoint, p-value, CI, safety)
• PDUFA date and review type confirmed on the FDA calendar or BioPharmCatalyst
• Position sized for the reality: higher approval odds, lower stock-moving potential
• Company market cap checked: mega-cap sBLAs move less, small-cap initial filings move more

For the full investing framework, see our How to Invest in Biotech Stocks guide.